Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 13, 2021
- Accepted in final form September 21, 2021
- First Published November 11, 2021.
Author Disclosures
- Markus Bock, MD,
- Falk Steffen, MD (f.steffen{at}uni-mainz.de),
- Frauke Zipp, MD (zipp{at}uni-mainz.de) and
- Stefan Bittner, MD (bittner{at}uni-mainz.de)
- Markus Bock, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Schär AG Burgstall, Italy
NONE
NONE
1) Myelin Projekt e.V., Germany 2) Familie Ernst Wendt Stiftung Köln, Germany
NONE
NONE
NONE
NONE
NONE
NONE
- Falk Steffen, MD (f.steffen{at}uni-mainz.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD (zipp{at}uni-mainz.de) and
(1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche
NONE
(1) Novartis (2) Octapharma (3) Merck Serono (4) ONO Pharma (5) Biogen (6) Genzyme (7) Celgene (8) Roche
(1) Brain, Associate Editor, 2021- (2) Science Translational Medicine, Advisor, 2021-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Genzyme
(1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2024 (2) DFG CRC1080, PI, 2013-2024 (3) BMBF HaltMS, PI, 2020-2023
NONE
(1) Progressive MS Alliance, BRAVEinMS
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Bittner, MD (bittner{at}uni-mainz.de)
NONE
NONE
S. B. has received funding for travel expenses for attending meetings from Novartis and Merck Serono and honoraria from Biogen Idec, BMS, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Council (DFG, CRC-TR-128)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (M.B., F.S., F.Z., S.B.), Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz; Institute of Biochemistry (M.B.), University Medicine Berlin—Charité, Germany; and Experimental & Clinical Research Center (ECRC) A Joint Cooperation of Charité Medical Faculty and Max-Delbrueck-Center for Molecular Medicine (MDC) (M.B.).
- Correspondence
Dr. Bock markus.bock{at}posteo.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.